Comparative pharmacokinetics [General Sta­tis­tics]

posted by JPL  – Vienna, 2009-01-09 10:28 (6372 d 22:19 ago) – Posting: # 3013
Views: 7,478

Dear Santosh,

if you do not know anything about the way "comparability" should be demonstrated (what is stated in the protocol?) you may define the AUC0.tlast as the primary endpoint and AUC0-Inf, MRT, IR, ... as secondary ones. However, meaningful parameters depend on the application route. Then you calculate the points estimates and 95% CI for each parameter, and the ratio and the corresponding 90% CI for the ratio. If you do not provide any CI for the ratio, it is hard to evaluate whether a difference really exists.
Regards,
JPL

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
143 visitors (0 registered, 143 guests [including 35 identified bots]).
Forum time: 09:47 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5